Gemcitabine-induced neutrophil extracellular traps via interleukin-8-CXCR1/2 pathway promote chemoresistance in pancreatic cancer

Br J Cancer. 2025 Dec;133(11):1640-1651. doi: 10.1038/s41416-025-03192-1. Epub 2025 Sep 25.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, and chemoresistance poses a significant challenge in its treatment. Neutrophil extracellular traps (NETs) have emerged as key players in the tumour microenvironment, but their role in chemoresistance remains unclear.

Methods: We investigated the involvement of NETs in PDAC chemoresistance using patient tumour samples, in vitro assays with gemcitabine (GEM)-treated PDAC cells, and in vivo mouse models. We evaluated cytokine production, NET formation and tumour response to GEM, with or without the CXCR1/2 inhibitor navarixin.

Results: NETs are significantly accumulated in the tumours of PDAC patients exhibiting poor response to chemotherapy. GEM-treated PDAC cells secrete pro-inflammatory cytokines such as interleukin-8 (IL-8). IL-8 promote the formation of chemotherapy-induced NETs (chemoNETosis) through activation of CXCR 1/2 on neutrophils. Importantly, treatment with navarixin significantly suppressed chemoNETosis, restored sensitivity to GEM, and significantly reduced tumour growth in vivo.

Conclusions: Our findings reveal that NETs contribute to chemoresistance in PDAC and that IL-8-mediated chemoNETosis plays a pivotal role in this process. Inhibition of CXCR1/2-mediated NET formation enhances the efficacy of GEM. This approach may represent a promising therapeutic strategy for overcoming chemoresistance in PDAC. These results support further clinical investigation of anti-NETs therapies.

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / pharmacology
  • Carcinoma, Pancreatic Ductal* / drug therapy
  • Carcinoma, Pancreatic Ductal* / metabolism
  • Carcinoma, Pancreatic Ductal* / pathology
  • Cell Line, Tumor
  • Deoxycytidine* / analogs & derivatives
  • Deoxycytidine* / pharmacology
  • Drug Resistance, Neoplasm*
  • Extracellular Traps* / drug effects
  • Extracellular Traps* / metabolism
  • Female
  • Gemcitabine
  • Humans
  • Interleukin-8* / metabolism
  • Male
  • Mice
  • Neutrophils / drug effects
  • Neutrophils / metabolism
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / metabolism
  • Pancreatic Neoplasms* / pathology
  • Receptors, Interleukin-8A* / metabolism
  • Receptors, Interleukin-8B* / metabolism
  • Signal Transduction / drug effects
  • Tumor Microenvironment / drug effects
  • Xenograft Model Antitumor Assays

Substances

  • Deoxycytidine
  • Interleukin-8
  • Receptors, Interleukin-8B
  • Receptors, Interleukin-8A
  • Gemcitabine
  • CXCR2 protein, human
  • CXCL8 protein, human
  • Antimetabolites, Antineoplastic